Medical Device and Diagnostic Industry (MD+DI)

FDA Approves Johnson & Johnson's Breakthrough Cataracts Solution

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...
Ophthalmology Times

FDA approves Johnson & Johnson's TECNIS PureSee EDOF IOL

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...
Ophthalmology Times

SpyGlass Pharma reports positive 12-month phase I/II results for BIM-IOL System in glaucoma and ocular hypertension

Randomization (2:1:1) compared 78 mcg or 39 mcg BIM-IOL plus artificial tears versus standard monofocal IOL plus twice-daily timolol, with IOP change assessed at early visits. Mean IOP reduction at 12 ...
The American Journal of Managed Care

Enhanced Monofocal Lenses May Provide Alternative in Glaucoma Treatment

Enhanced monofocal IOLs may improve intermediate vision and preserve visual function in glaucoma patients. The study showed significant improvements in BCVA, RNFLT, and IOP for both enhanced and ...

J&J wins FDA nod for Tecnis PureSee intraocular lens

Johnson & Johnson (JNJ) wins FDA approval for Tecnis PureSee intraocular lens ((IOL)), giving eye surgeons a new lens option for use in cataract surgery. Read more here.
Nasdaq

New Head-to-Head Data Show Clareon Monofocal IOLs and TECNIS Eyhance Monofocal IOLs Provide Similar Range of Vision

FORT WORTH, Texas--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced results from a new study presented at the ...
The American Journal of Managed Care

Teprotumumab, Enhanced Monofocal IOLs Among Hot Topics at AAO 2021

Among many presentations during a hot topics session at the American Academy of Ophthalmology 2021 annual meeting, speakers discussed the first FDA approved therapy for thyroid eye disease and the ...
Healio

Bimatoprost implant reduces IOP, improves vision at 12 months

At 12 months in a phase 1/2 trial, the Bimatoprost Drug Pad-IOL System improved IOP, vision and treatment burden in patients ...
Nasdaq

Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the ...
Healio

Multifocal IOLs significantly reduce spectacle use in mild to moderate glaucoma

Please provide your email address to receive an email when new articles are posted on . Significantly more patients with multifocal IOLs were spectacle-free for near tasks than those with monofocal ...